0000950103-22-013936.txt : 20220811 0000950103-22-013936.hdr.sgml : 20220811 20220811170803 ACCESSION NUMBER: 0000950103-22-013936 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220630 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220811 DATE AS OF CHANGE: 20220811 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Acutus Medical, Inc. CENTRAL INDEX KEY: 0001522860 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 451306615 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-39430 FILM NUMBER: 221156863 BUSINESS ADDRESS: STREET 1: 2210 FARADAY AVE STREET 2: SUITE 100 CITY: CARLSBAD STATE: CA ZIP: 92008 BUSINESS PHONE: 442-232-6080 MAIL ADDRESS: STREET 1: 2210 FARADAY AVE STREET 2: SUITE 100 CITY: CARLSBAD STATE: CA ZIP: 92008 8-K/A 1 dp178541_8ka.htm FORM 8-K/A
0001522860 true NASDAQ 0001522860 2022-06-30 2022-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K/A

 

 

 

Amendment No. 1 to

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 11, 2022 (June 30, 2022)

 

 

 

afib-20220330_g1.jpg

 

Acutus Medical, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware 001-39430 45-1306615

(State or Other Jurisdiction

of Incorporation)

 (Commission File Number)

(IRS Employer

Identification No.)

     

2210 Faraday Ave., Suite 100

Carlsbad, CA

   92008
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (442) 232-6080

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

_________________________________________

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered
Common Stock, par value $0.001 AFIB The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

  

 

 

  

EXPLANATORY NOTE

 

This Amendment No. 1 to Form 8-K (“Form 8-K/A”) amends the Current Report on Form 8-K filed by Acutus Medical, Inc. (the “Company”), with the Securities and Exchange Commission (“SEC”) on July 1, 2022 (the “Original Filing”). As disclosed in the Original Filing, on June 30, 2022, the Company completed the first of two closings in connection with the previously disclosed sale of its AcQCross® line of sheath-compatible septal crossing devices, AcQGuide® MINI integrated crossing device and sheath, AcQGuide® FLEX Steerable Introducer with integrated transseptal dilator and needle, and AcQGuide® VUE steerable sheaths (the “Seller Products”) to Medtronic, Inc. pursuant to an asset purchase agreement dated April 26, 2022 (the “Transaction”). This Form 8-K/A is being filed solely for the purposes of updating the unaudited pro forma financial information relating to the sale of the Seller Products to include the unaudited pro forma consolidated statement of operations for the six months ended June 30, 2022, giving pro forma effect to the sale of the Seller Products. This Form 8-K/A does not change any of the other information contained in the Original Filing except as specifically set forth herein. This Form 8-K/A continues to speak as of the date of the Original Filing and we have not updated or amended any disclosures, except as specifically set forth herein, contained in the Original Filing to reflect events that have occurred since the time of the Original Filing.

 

Item 8.01 Other Events

 

The Company’s unaudited pro forma consolidated balance sheet as of March 31, 2022 and unaudited pro forma consolidated statements of operations for the three months ended March 31, 2022 and fiscal year ended December 31, 2021, in each case giving pro forma effect to the sale of the Seller Products, and the notes related thereto, are filed as Exhibit 99.1 to this Form 8-K/A and incorporated herein by reference. The Company’s unaudited pro forma consolidated statement of operations for the six months ended June 30, 2022, and the notes related thereto, are filed as Exhibit 99.2 to this Form 8-K/A and incorporated herein by reference. The Transaction is reflected in the Company’s condensed consolidated balance sheet as of June 30, 2022 included in the Company’s Quarterly Report on Form 10-Q, filed with the SEC on August 11, 2022. Accordingly, the Company has not included an unaudited pro forma consolidated balance sheet as of June 30, 2022 in this Form 8-K/A.

 

Cautionary Note Regarding Forward-Looking Statements

 

This Current Report on Form 8-K and certain information incorporated by reference herein contain forward-looking statements within the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements included or incorporated by reference in this Current Report, other than statements that are purely historical, are forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” “will,” “should,” “would,” “could,” “may” and similar expressions also identify forward-looking statements. The forward-looking statements include, without limitation, statements regarding whether and when the transactions contemplated by the Sale Agreement (including the Second Closing (as defined in the Original 8-K) and earnout payments thereunder), the Warrants (as defined in the Original 8-K) (including exercise thereof) and ancillary agreements will be consummated.

 

 

 

 

Our expectations, beliefs, objectives, intentions and strategies regarding future results are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from results contemplated by our forward-looking statements. Factors that may affect the actual results achieved by the Company include, without limitation, the parties’ ability to consummate the transactions; satisfaction of conditions in connection with the transactions described herein; the parties’ ability to meet expectations regarding the timing and completion of the transactions; and the risk factors listed from time to time in the Company’s filings with the SEC, as further described below.

 

We urge you to carefully consider risks and uncertainties and review the additional disclosures we make concerning risks and uncertainties that may materially affect the outcome of our forward-looking statements and our future business and operating results, including those made under the captions “Risk Factors” contained in our most recently filed Form 10-K and Form 10-Q and subsequent filings with the SEC. We assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of the filing of this Current Report on Form 8-K.

 

Item 9.01 Exhibits

 

(b) Pro forma financial information.

 

Attached as Exhibit 99.1 hereto and incorporated by reference are an unaudited pro forma consolidated balance sheet as of March 31, 2022 and unaudited pro forma consolidated statements of operation for the three months ended March 31, 2022 and fiscal year ended December 31, 2021, in each case giving pro forma effect to the sale of the Seller Products.

 

Attached as Exhibit 99.2 hereto and incorporated by reference is an unaudited pro forma consolidated statement of operation for the six months ended June 30, 2022, giving pro forma effect to the sale of the Seller Products.

 

(d)Exhibits

 

 

Exhibit Number Description
   
2.1*^ Asset Purchase Agreement dated April 26, 2022, by and among Medtronic, Inc. and Acutus Medical, Inc.
   
10.1*^ Amended and Restated Credit Agreement dated June 30, 2022, by and among Acutus Medical, Inc., the lenders from time to time party thereto, and Wilmington Trust, National Association, as Administrative Agent
   
10.2*^ Warrant Purchase Agreement dated June 30, 2022, by and among Acutus Medical, Inc. and the purchasers named therein
   
10.3*^ Form of Warrant for the issuance of warrants dated June 30, 2022
   
10.4*^ Registration Rights Agreement dated June 30, 2022, by and among Acutus Medical, Inc., Deerfield Partners, L.P. and Deerfield Private Design Fund III, L.P.
   
99.1^ Unaudited pro forma consolidated balance sheet as of March 31, 2022 and unaudited pro forma consolidated statements of operation for the three months ended March 31, 2022 and fiscal year ended December 31, 2021
   
99.2 Unaudited pro forma consolidated statement of operation for the six months ended June 30, 2022, giving pro forma effect to the sale of the Seller Products
   
99.3**^ Press Release dated July 1, 2022
   
104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

* The schedules and exhibits to the exhibited agreements have been omitted from this filing pursuant to Item 601(b)(2) of Regulation S-K. The Company will furnish copies of any such schedules and exhibits to the Securities and Exchange Commission upon request.

 ** Furnished herewith, not filed. 

 ^ Previously filed.

 

 

 

  

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: August 11, 2022

 

     
  Acutus Medical, Inc.
     
  By: /s/ David Roman
    David Roman
    President, Chief Executive Officer, Chief Financial Officer and Director

 

 

 EX-99.2 2 dp178541_ex9902.htm EXHIBIT 99.2

Exhibit 99.2

 

Unaudited Pro Forma Condensed Consolidated Financial Information

 

Overview

 

On June 30, 2022 (the “Effective Date”), Acutus Medical, Inc. (“Acutus” or the “Company”) completed its previously announced transaction with Medtronic, Inc. (together with its affiliates, “Medtronic”), in accordance with the Asset Purchase Agreement (the “Agreement”) executed on April 26, 2022, and pursuant to which the Company sold to Medtronic certain transseptal access and sheath assets (the "Assets"). The Assets include patents, trademarks, patent and trademark applications, know-how, copyrights, prototypes and other intellectual property owned or licensed by the Company, business records and documents (including regulatory and clinical materials), and manufacturing equipment related to the AcQCross® line of sheath-compatible septal crossing devices, AcQGuide® MINI integrated crossing device and sheath, AcQGuide® FLEX Steerable Introducer with integrated transseptal dilator and needle, and AcQGuide® VUE steerable sheaths (the “Products”).

 

The following unaudited pro forma condensed consolidated financial statements are intended to show how the transaction might have affected the historical financial statements of Acutus if the transaction had been completed at an earlier time as indicated therein. The unaudited pro forma condensed consolidated financial statements have been prepared in accordance with Article 11 of Regulation S-X and were derived from the Company’s historical consolidated financial statements and are being presented to give effect to the sale of the Assets. The unaudited pro forma condensed consolidated financial statements should be read in conjunction with:

 

  i.

The accompanying notes to the unaudited pro forma condensed consolidated financial statements;

 

  ii.

The audited historical financial statements of the Company and its subsidiaries, the accompanying notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 30, 2022; and

 

  iii. The unaudited interim historical consolidated financial statements of the Company and its subsidiaries, the accompanying notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in the Company’s Quarterly Report on Form 10-Q for the six months ended June 30, 2022 filed with the SEC on August 11, 2022.

 

The unaudited pro forma condensed consolidated financial statements of the Company are based on available information and assumptions that the Company’s management believes are reasonable as of the date of this filing. The unaudited pro forma condensed consolidated statements of operations for the year ended December 31, 2021 and the six months ended June 30, 2022 present the Company’s results of operations as if the transaction had occurred on January 1, 2021, the beginning of the earliest period presented. An unaudited pro forma condensed consolidated balance sheet is not presented as the transaction closed on June 30, 2022 and the balance sheet effects of the transaction are already included in the Company's condensed consolidated balance sheet as of June 30, 2022.

 

The unaudited pro forma condensed consolidated financial statements do not purport to represent the Company’s actual consolidated results of operations or financial condition had the transaction occurred on the date assumed, nor are they indicative of the Company’s future consolidated results of operations or financial condition.

 

Article 11 of Regulation S-X. Article 11 of Regulation S-X requires that pro forma financial information include the following pro forma adjustments to the historical financial statements of the registrant as follows:

 

  · Transaction Accounting Adjustments - Adjustments that reflect only the application of required accounting to the acquisition, disposition, or other transaction.
     
  · Autonomous Entity Adjustments - Adjustments that are necessary to reflect the operations and financial position of the registrant if the registrant was previously part of another entity. There are no autonomous entity adjustments included in the pro forma financial information since the Company currently operates, and after the completion of the transaction will continue to operate, as an independent, standalone entity.

 

 

 

In addition, Regulation S-X permits registrants to reflect adjustments that depict synergies and dis-synergies of the acquisitions and dispositions for which pro forma effect is being given in our disclosures as management adjustments. The unaudited pro forma condensed consolidated financial statements do not include management adjustments to reflect any potential synergies that may be achievable, or dis-synergy costs that may occur, in connection with the sale of the Assets. The Company has determined not to reflect such adjustments because it does not believe presenting such adjustments would enhance an understanding of the pro forma effects of the transaction.

 

The transaction accounting adjustments to reflect the sale of the Assets in the unaudited pro forma condensed consolidated financial statements include:

 

  · The sale of the Assets pursuant to the Agreement and the elimination of operating results related to the Assets.

 

  · The estimated gain on the sale of the Assets.

 

The unaudited pro forma condensed consolidated financial statements are presented for informational purposes only and are based upon estimates by the Company’s management, which are based upon available information and certain assumptions that the Company’s management believes are reasonable as of the date of this filing. The unaudited pro forma condensed consolidated financial statements are not intended to be results of operations that would have been achieved had the transaction been consummated as of the date indicated above, nor does it purport to indicate results which may be attained in the future. Actual amounts could differ materially from these estimates.

 

 

 

ACUTUS MEDICAL, INC.

Pro Forma Condensed Consolidated Statement of Operations

For the six months ended June 30, 2022

(Unaudited)

 

   Historical Acutus  Transaction Accounting Adjustments   
   (a)  (b)  Notes  Pro Forma
(in thousands, except share and per share amounts)            
Revenue  $7,757   $(1,300)   (1)  $6,457 
                     
Costs and operating expenses                    
      Cost of products sold   16,638    (1,145)   (1)   15,493 
      Research and development   15,938    (308)   (1)   15,630 
      Selling, general and administrative   28,528    (218)   (1)   28,310 
      Goodwill impairment   12,026    —           12,026 
      Restructuring   949    —           949 
      Change in fair value of contingent consideration   955    —           955 
      Gain on sale of business   (43,575)   43,575    (1)   —   
Total costs and operating expenses   31,459    41,904         73,363 
Loss from operations   (23,702)   (43,204)        (66,906)
                     
Total other expense, net                    
  Loss on debt extinguishment   (7,947)   —           (7,947)
  Interest income   51    —           51 
  Interest expense   (2,701)   —           (2,701)
Total other expense, net   (10,597)   —           (10,597)
Loss before income taxes   (34,299)   (43,204)        (77,503)
 Income tax benefit   —      —           —   
Net loss  $(34,299)  $(43,204)       $(77,503)
                     
                     
Net loss per common share, basic and diluted  $(1.22)            $(2.75)
Weighted average shares outstanding, basic and diluted   28,229,338              28,229,338 

 

See accompanying notes to the unaudited pro forma condensed consolidated financial statements.

 

 

 

ACUTUS MEDICAL, INC.

Pro Forma Condensed Consolidated Statement of Operations

For the year ended December 31, 2021

(Unaudited)

 

   Historical Acutus  Transaction Accounting Adjustments   
   (a)  (b)  Notes  Pro Forma
(in thousands, except share and per share amounts)            
Revenue  $17,263   $(1,967)   (1)  $15,296 
                     
Costs and operating expenses                    
      Cost of products sold   32,925    (1,845)   (1)   31,080 
      Research and development   36,683    (890)   (1)   35,793 
      Selling, general and administrative   63,523    (574)   (1)   62,949 
      Change in fair value of contingent consideration   (3,746)   —           (3,746)
      Gain on sale of business   —      (43,459)   (1)   (43,459)
Total costs and operating expenses   129,385    (46,768)        82,617 
Loss from operations   (112,122)   44,801         (67,321)
                     
Total other expense, net                    
  Interest income   116    —           116 
  Interest expense   (5,677)   —           (5,677)
Total other expense, net   (5,561)   —           (5,561)
Loss before income taxes   (117,683)   44,801         (72,882)
 Income tax benefit   —      —           —   
Net loss  $(117,683)  $44,801        $(72,882)
                     
Net loss per common share, basic and diluted  $(4.11)            $(2.54)
Weighted average shares outstanding, basic and diluted   28,654,313              28,654,313 

 

See accompanying notes to unaudited pro forma condensed consolidated financial statements.

 

 

 

Notes to the Unaudited Pro Forma Condensed Consolidated Financial Statements

 

On June 30, 2022 (the “Effective Date”), Acutus Medical, Inc. (the “Company”) completed its previously announced transaction with Medtronic, Inc. (together with its affiliates, “Medtronic”), in accordance with the Asset Purchase Agreement (the “Agreement”) executed on April 26, 2022, and pursuant to which the Company sold to Medtronic certain transseptal access and sheath assets (the "Assets"). The Assets include patents, trademarks, patent and trademark applications, know-how, copyrights, prototypes and other intellectual property owned or licensed by the Company, business records and documents (including regulatory and clinical materials) and manufacturing equipment related to the AcQCross® line of sheath-compatible septal crossing devices, AcQGuide® MINI integrated crossing device and sheath, AcQGuide® FLEX Steerable Introducer with integrated transseptal dilator and needle, and AcQGuide® VUE steerable sheaths (the “Products”). Pursuant to the Agreement, Medtronic paid $50.0 million at the first closing (“First Closing”) for, among other things, intellectual property rights to the Products and certain equipment used in the manufacturing of the Products, of which $4.0 million was paid into an indemnity escrow account for a period of 18 months following the First Closing. The Company is also eligible to receive the following contingent cash consideration pursuant to the Agreement;

 

(i)$20.0 million upon the Company’s completion, to the reasonable satisfaction of Medtronic, of certain conditions set forth in the Agreement relating to the Company becoming a qualified supplier of Medtronic for the Products, including demonstration of ISO 14971:2019 compliance, completion of certain test method validations and compliance with certain other reporting requirements (the “OEM Earnout”);

 

(ii)$17.0 million upon the earlier of (A) the Second Closing (as defined below) or (B) the Company’s initial submission for CE Mark certification of the Products under the European Union Medical Devices Regulation, to the reasonable satisfaction of a third-party regulatory consultant; subject to certain other conditions as set forth in the Agreement (the “Transfer Earnout”). The Transfer Earnout will be reduced to $13.0 million if the Second Closing does not occur, or if the Transfer Earnout is not achieved, within 15 months of the First Closing; and

 

(iii)amounts equal to 100%, 75%, 50% and 50% of Net Sales (as defined in the Agreement) from the Products achieved over each of the four years, respectively, following Medtronic’s first commercial sale of a Product after achievement of the OEM Earnout.

 

None of the above milestones were achieved as of June 30, 2022.

 

A second closing will occur on a date determined by Medtronic but no later than the fourth anniversary of the First Closing, subject to the satisfaction of customary closing conditions (the “Second Closing”). The Agreement provides that the Company may continue to sell the Products to third parties prior to achievement of the OEM Earnout. Following achievement of the OEM Earnout, the Company will manufacture the Products exclusively for Medtronic pursuant to a distribution agreement executed between the parties. At the Second Closing, Medtronic will acquire certain additional assets relating to the Products, primarily supplier agreements and permits and design and specification files required for Medtronic to become the manufacturer of record of the Products.

 

The unaudited pro forma condensed consolidated financial statements reflect the following:

 

  (a) The Company’s condensed consolidated statements of operations for the year ended December 31, 2021 and for the six months ended June 30, 2022.

 

  (b) Adjustments to reflect the sale of the Assets pursuant to the Agreement. Specific adjustments related to this presentation include the following:

 

  (1).

Adjustments to eliminate the revenue, costs of products sold, and operating expenses of the Assets for the periods presented.

 

As described above the pro forma statements of operations present the Company’s results as if the transaction had occurred on January 1, 2021.  No proceeds from earnout payments were included in the pro forma financial statements as they are contingent upon certain milestones and will be accounted for upon the achievement of such milestones. The estimated gain of $43.9 million related to the sale of the Assets has been included in the pro forma condensed consolidated statement of operations for the year ended December 31, 2021.

 

 

 

 

 

 

 

 GRAPHIC 3 image_003.jpg GRAPHIC begin 644 image_003.jpg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end EX-101.SCH 4 afib-20220630.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 afib-20220630_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 afib-20220630_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Cover
Jun. 30, 2022
Cover [Abstract]  
Document Type 8-K/A
Amendment Flag true
Amendment Description This Amendment No. 1 to Form 8-K (“Form 8-K/A”) amends the Current Report on Form 8-K filed by Acutus Medical, Inc. (the “Company”), with the Securities and Exchange Commission (“SEC”) on July 1, 2022 (the “Original Filing”). As disclosed in the Original Filing, on June 30, 2022, the Company completed the first of two closings in connection with the previously disclosed sale of its AcQCross® line of sheath-compatible septal crossing devices, AcQGuide® MINI integrated crossing device and sheath, AcQGuide® FLEX Steerable Introducer with integrated transseptal dilator and needle, and AcQGuide® VUE steerable sheaths (the “Seller Products”) to Medtronic, Inc. pursuant to an asset purchase agreement dated April 26, 2022 (the “Transaction”). This Form 8-K/A is being filed solely for the purposes of updating the unaudited pro forma financial information relating to the sale of the Seller Products to include the unaudited pro forma consolidated statement of operations for the six months ended June 30, 2022, giving pro forma effect to the sale of the Seller Products. This Form 8-K/A does not change any of the other information contained in the Original Filing except as specifically set forth herein. This Form 8-K/A continues to speak as of the date of the Original Filing and we have not updated or amended any disclosures, except as specifically set forth herein, contained in the Original Filing to reflect events that have occurred since the time of the Original Filing.
Document Period End Date Jun. 30, 2022
Entity File Number 001-39430
Entity Registrant Name Acutus Medical, Inc.
Entity Central Index Key 0001522860
Entity Tax Identification Number 45-1306615
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 2210 Faraday Ave.
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Carlsbad
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92008
City Area Code 442
Local Phone Number 232-6080
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001
Trading Symbol AFIB
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
XML 8 dp178541_8ka_htm.xml IDEA: XBRL DOCUMENT 0001522860 2022-06-30 2022-06-30 iso4217:USD shares iso4217:USD shares 0001522860 true NASDAQ 8-K/A 2022-06-30 Acutus Medical, Inc. DE 001-39430 45-1306615 2210 Faraday Ave. Suite 100 Carlsbad CA 92008 442 232-6080 false false false false Common Stock, par value $0.001 AFIB true false This Amendment No. 1 to Form 8-K (“Form 8-K/A”) amends the Current Report on Form 8-K filed by Acutus Medical, Inc. (the “Company”), with the Securities and Exchange Commission (“SEC”) on July 1, 2022 (the “Original Filing”). As disclosed in the Original Filing, on June 30, 2022, the Company completed the first of two closings in connection with the previously disclosed sale of its AcQCross® line of sheath-compatible septal crossing devices, AcQGuide® MINI integrated crossing device and sheath, AcQGuide® FLEX Steerable Introducer with integrated transseptal dilator and needle, and AcQGuide® VUE steerable sheaths (the “Seller Products”) to Medtronic, Inc. pursuant to an asset purchase agreement dated April 26, 2022 (the “Transaction”). This Form 8-K/A is being filed solely for the purposes of updating the unaudited pro forma financial information relating to the sale of the Seller Products to include the unaudited pro forma consolidated statement of operations for the six months ended June 30, 2022, giving pro forma effect to the sale of the Seller Products. This Form 8-K/A does not change any of the other information contained in the Original Filing except as specifically set forth herein. This Form 8-K/A continues to speak as of the date of the Original Filing and we have not updated or amended any disclosures, except as specifically set forth herein, contained in the Original Filing to reflect events that have occurred since the time of the Original Filing. EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 25 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://acutusmedical.com/role/Cover Cover Cover 1 false false All Reports Book All Reports dp178541_8ka.htm afib-20220630.xsd afib-20220630_lab.xml afib-20220630_pre.xml dp178541_ex9902.htm image_003.jpg http://xbrl.sec.gov/dei/2021q4 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "dp178541_8ka.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "dp178541_8ka.htm" ] }, "labelLink": { "local": [ "afib-20220630_lab.xml" ] }, "presentationLink": { "local": [ "afib-20220630_pre.xml" ] }, "schema": { "local": [ "afib-20220630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 25, "memberCustom": 0, "memberStandard": 0, "nsprefix": "AFIB", "nsuri": "http://acutusmedical.com/20220630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "dp178541_8ka.htm", "contextRef": "From2022-06-30to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://acutusmedical.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "dp178541_8ka.htm", "contextRef": "From2022-06-30to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://acutusmedical.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 16 0000950103-22-013936-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950103-22-013936-xbrl.zip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end